Literature DB >> 16740195

Prevalence of enteric bacteria that inhibit growth of enterohaemorrhagic Escherichia coli O157 in humans.

H Toshima1, M Hachio, Y Ikemoto, J Ogasawara, A Hase, K Takahashi, H Masaki, Y Nishikawa.   

Abstract

Enterohaemorrhagic Escherichia coli O157 (O157) is infectious to humans, particularly children, at very low doses and causes not only haemorrhagic colitis but also other serious symptoms. To investigate an association between intestinal bacterial flora and resistance to such infections, we screened faecal samples for the presence of enteric bacteria that are able to suppress the growth of O157. Samples from 303 individuals, 35 children (aged < or =6 years) and 268 adults (aged 20-59 years), were examined. Colonies with different appearances on sorbitol MacConkey agar medium were screened for the production of bacteriocins inhibitory for O157 in an overlay agar plate assay. O157-inhibiting strains were isolated from 52 individuals. The prevalence of these bacteria tended to rise with age, and was significantly higher among 40- to 59-year-old adults (23/101, 22.8%) than among children (3/35, 8.6%; P<0.05). To test the hypothesis that these bacteriocin-producing strains contribute to resistance against O157 in human adults, we examined faecal samples of 25 healthy O157 carriers. Inhibitory bacteria were more prevalent among the latter (9/25, 36.0%) than among age-matched subjects who did not carry O157 (49/268, 18.3%). It appears, therefore, that inhibitory bacteria in the human gut may play a role in inhibiting propagation of O157 and/or suppressing expression of virulence factors by this pathogen.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16740195      PMCID: PMC2870543          DOI: 10.1017/S0950268806006510

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  28 in total

1.  Evidence of persisting serum antibodies to Escherichia coli O157 lipopolysaccharide and Verocytotoxin in members of rural communities in England.

Authors:  J Evans; R M Chalmers; H Chart; R L Salmon; S M Kench; T J Coleman; D Meadows; P Morgan-Capner; P Softley; M Sillis; D R Thomas
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

2.  Molecular analysis of enterohemorrhagic Escherichia coli isolates in Japan and its application to epidemiological investigation.

Authors:  H Watanabe; J Terajima; H Izumiya; A Wada; K Tamura
Journal:  Pediatr Int       Date:  1999-04       Impact factor: 1.524

3.  Outbreaks of enterohaemorrhagic Escherichia coli O157:H7 infection by two different genotype strains in Japan, 1996.

Authors:  H Watanabe; A Wada; Y Inagaki; K Itoh; K Tamura
Journal:  Lancet       Date:  1996-09-21       Impact factor: 79.321

4.  Neutralizing antibodies to Escherichia coli Vero cytotoxin 1 and antibodies to O157 lipopolysaccharide in healthy farm family members and urban residents.

Authors:  D Reymond; R P Johnson; M A Karmali; M Petric; M Winkler; S Johnson; K Rahn; S Renwick; J Wilson; R C Clarke; J Spika
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

5.  Human Escherichia coli O157:H7 infection associated with the consumption of unpasteurized goat's milk.

Authors:  M Bielaszewska; J Janda; K Bláhová; H Minaríková; E Jíková; M A Karmali; J Laubová; J Sikulová; M A Preston; R Khakhria; H Karch; H Klazarová; O Nyc
Journal:  Epidemiol Infect       Date:  1997-12       Impact factor: 2.451

6.  Reduction of carriage of enterohemorrhagic Escherichia coli O157:H7 in cattle by inoculation with probiotic bacteria.

Authors:  T Zhao; M P Doyle; B G Harmon; C A Brown; P O Mueller; A H Parks
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

7.  Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise.

Authors:  J R Johnson; A L Stell
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

8.  Inhibition of Listeria monocytogenes in a pork product by a Lactobacillus sake strain.

Authors:  E C De Martinis; B D Franco
Journal:  Int J Food Microbiol       Date:  1998-06-30       Impact factor: 5.277

9.  Evaluation of colicins for inhibitory activity against diarrheagenic Escherichia coli strains, including serotype O157:H7.

Authors:  S E Murinda; R F Roberts; R A Wilson
Journal:  Appl Environ Microbiol       Date:  1996-09       Impact factor: 4.792

10.  Shiga toxin-producing Escherichia coli O157:H7 in Japan.

Authors:  J Terajima; H Izumiya; A Wada; K Tamura; H Watanabe
Journal:  Emerg Infect Dis       Date:  1999 Mar-Apr       Impact factor: 6.883

View more
  5 in total

Review 1.  Shiga toxin-producing Escherichia coli O104:H4: a new challenge for microbiology.

Authors:  Maite Muniesa; Jens A Hammerl; Stefan Hertwig; Bernd Appel; Harald Brüssow
Journal:  Appl Environ Microbiol       Date:  2012-04-13       Impact factor: 4.792

2.  Crystal structure of the full-length ATPase GspE from the Vibrio vulnificus type II secretion system in complex with the cytoplasmic domain of GspL.

Authors:  Connie Lu; Konstantin V Korotkov; Wim G J Hol
Journal:  J Struct Biol       Date:  2014-08-01       Impact factor: 2.867

Review 3.  Trading molecules and tracking targets in symbiotic interactions.

Authors:  Eric W Schmidt
Journal:  Nat Chem Biol       Date:  2008-08       Impact factor: 15.040

4.  Enhancement of Shiga toxin production in enterohemorrhagic Escherichia coli serotype O157:H7 by DNase colicins.

Authors:  Hirono Toshima; Ayana Yoshimura; Kentaro Arikawa; Ayumi Hidaka; Jun Ogasawara; Atsushi Hase; Haruhiko Masaki; Yoshikazu Nishikawa
Journal:  Appl Environ Microbiol       Date:  2007-10-12       Impact factor: 4.792

5.  Escherichia coli bacteriocins: antimicrobial efficacy and prevalence among isolates from patients with bacteraemia.

Authors:  Maruška Budič; Matija Rijavec; Ziva Petkovšek; Darja Zgur-Bertok
Journal:  PLoS One       Date:  2011-12-19       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.